Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints

Journal of Clinical Microbiology
M A PfallerD W Warnock

Abstract

Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between the in vitro activity and outcome from both in vivo and clinical studies. Using data generated by standardized broth microdilution and disk diffusion test methods, the Antifungal Susceptibility Subcommittee of the Clinical and Laboratory Standards Institute has now proposed interpretive breakpoints for voriconazole and Candida species. The MIC distribution for voriconazole was determined using a collection of 8,702 clinical isolates. The overall MIC90 was 0.25 microg/ml and 99% of the isolates were inhibited at < or = 1 microg/ml of voriconazole. Similar results were obtained for 1,681 Candida isolates (16 species) from the phase III clinical trials. Analysis of the available data for 249 patients from six phase III voriconazole clinical trials demonstrated a statistically significant correlation (P = 0.021) between MIC and investigator end-of-treatment assessment of outcome. Consistent with parallel pharmacodynamic analyses, these data support the following MIC breakpoints for voriconazole and Candida species: susceptible (S), < or...Continue Reading

References

Dec 1, 1974·The Journal of Infectious Diseases·C M Metzler, R M DeHaan
Jan 9, 1999·Clinical Microbiology Reviews·D J SheehanC M Sibley
Aug 12, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M Cuenca-EstrellaJ L Rodríguez-Tudela
Sep 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R AllyUNKNOWN Esophageal Candidiasis Study Group
Jan 25, 2002·The New England Journal of Medicine·Thomas J WalshUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group
Feb 28, 2002·Expert Opinion on Investigational Drugs·Holly L Hoffman, R Chris Rathbun
May 23, 2002·Journal of Medical Microbiology·René PelletierEmidio De Carolis
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·L PurkinsD Kleinermans
Aug 9, 2002·The New England Journal of Medicine·Raoul HerbrechtUNKNOWN Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillu
Oct 2, 2002·Journal of Clinical Microbiology·M A Pfaller, D J Diekema
Oct 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John H Rex, Michael A Pfaller
Mar 18, 2003·The Annals of Pharmacotherapy·Margaret M PearsonStanley W Chapman
Mar 26, 2003·Antimicrobial Agents and Chemotherapy·David Andes
Apr 26, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John R PerfectElizabeth Johnson
Jun 5, 2003·Drugs of Today·P. H. Chandrasekar, E. Manavathu
Jun 25, 2003·Current Opinion in Infectious Diseases·Thomas A Clark, Rana A Hajjeh
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Luis Ostrosky-ZeichnerJeannette Lee
Nov 18, 2003·British Journal of Clinical Pharmacology·Lynn PurkinsDon Nichols
Dec 10, 2003·Journal of Clinical Microbiology·Kevin C HazenUNKNOWN Global Antifungal Surveillance Group
Jan 30, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M A PfallerUNKNOWN International Fungal Surveillance Participant Group

❮ Previous
Next ❯

Citations

Jul 30, 2010·European Journal of Clinical Pharmacology·Hui-Yan ShiDong-Sheng Ouyang
Jan 22, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S Costa-de-OliveiraA Gonçalves Rodrigues
Oct 28, 2009·Current Infectious Disease Reports·Jeannina A Smith
Feb 11, 2011·Current Infectious Disease Reports·Susanne PerkhoferCornelia Lass-Flörl
Sep 22, 2007·Medical Mycology·Sevtap Arikan
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andres PascualOscar Marchetti
Dec 3, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael NeelyJill Hoffman
Jun 23, 2010·Antimicrobial Agents and Chemotherapy·Jesús GuineaEmilio Bouza
Oct 29, 2008·Antimicrobial Agents and Chemotherapy·David AndesOscar Marchetti
Nov 8, 2006·Antimicrobial Agents and Chemotherapy·Andres PascualOscar Marchetti
Jan 31, 2007·Antimicrobial Agents and Chemotherapy·Vânia Lúcia Ribeiro da MattaAnna S Levin
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·D AndesA Lepak
Feb 2, 2011·Antimicrobial Agents and Chemotherapy·M Cuenca-EstrellaUNKNOWN Antifungal Subcommittee of European Committee on Antimicrobial Susceptibility Testing
Jan 16, 2007·Clinical Microbiology Reviews·M A Pfaller, D J Diekema
Jun 6, 2007·Journal of Clinical Microbiology·Maiken Cavling ArendrupJ H Rex
Jun 1, 2012·Journal of Clinical Microbiology·Andrew M BormanElizabeth M Johnson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

© 2021 Meta ULC. All rights reserved